Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Resolvin E1 (RvE1) is a naturally occurring lipid‐derived mediator generated during the resolution of inflammation. The anti‐inflammatory effects of RvE1 have been demonstrated in a variety of disease settings; however, it is not known whether RvE1 may also exert direct anti‐fibrotic effects. We examined the potential anti‐fibrotic actions of RvE1 in the mouse obstructed kidney—a model in which tissue fibrosis is driven by unilateral ureteric obstruction (UUO), an irreversible, non‐immune insult. Administration of RvE1 (300 ng/day) to mice significantly reduced accumulation of α‐smooth muscle actin (SMA)+ myofibroblasts and the deposition of collagen IV on day 6 after UUO. This protective effect was associated with a marked reduction of myofibroblast proliferation on days 2, 4 and 6 after UUO. RvE1 treatment also inhibited production of the major fibroblast mitogen, platelet‐derived growth factor‐BB (PDGF‐BB), in the obstructed kidney. Acute resolvin treatment over days 2–4 after UUO also had a profound inhibitory effect upon myofibroblast proliferation without affecting the PDGF expression, suggesting a direct effect upon fibroblast proliferation. In vitro studies established that RvE1 can directly inhibit PDGF‐BB‐induced proliferation in primary mouse fibroblasts. RvE1 induced transient, but not sustained, activation of the pro‐proliferative ERK and AKT signalling pathways. Of note, RvE1 inhibited the sustained activation of ERK and AKT pathways seen in response to PDGF stimulation, thereby preventing up‐regulation of molecules required for progression through the cell cycle (c‐Myc, cyclin D) and down‐regulation of inhibitors of cell cycle progression (p21, cip1). Finally, siRNA‐based knock‐down studies showed that the RvE1 receptor, ChemR23, is required for the anti‐proliferative actions of RvE1 in cultured fibroblasts. In conclusion, this study demonstrates that RvE1 can inhibit fibroblast proliferation in vivo and in vitro, identifying RvE1 as a novel anti‐fibrotic therapy. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189
Hong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562
Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis
Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T. E., & Serhan, C. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.044131 · Cited by 278
Ho, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H. K., Pande, R., Creager, M. A., Serhan, C. N., & Conte, M. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091082 · Cited by 204
Cited by
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033
Self-citationSpecialized pro-resolving mediators: endogenous regulators of infection and inflammation
Basil, M. C., & Levy, B. D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.4 · Cited by 791
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 555
Lipid Mediators in the Resolution of Inflammation
Serhan, C. N., Chiang, N., Dalli, J., & Levy, B. D. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016311 · Cited by 544
Resolution phase lipid mediators of inflammation: agonists of resolution
Serhan, C. N., & Chiang, N. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.012 · Cited by 331
Chiang, N., & Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.005 · Cited by 324
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Dobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 268
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
Brennan, E., Kantharidis, P., Cooper, M. E., & Godson, C. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00454-y · Cited by 262
Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.001 · Cited by 257
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217
“AQP4, aquaporin 4; ATRA, all-trans retinoic acid; AT-RvD3, aspirin-triggered resolvin; BMDM, bone marrow-derived macrophages; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DC, dendritic cell; EAE, experimental autoimmune encephalitis; GRK, GPCR kinase; OGD, oxygen-glucose deprivation; LX, l…”
BackgroundInfluentialFerreira, I., Falcato, F., Bandarra, N., & Rauter, A. P. (2022) · Molecules · doi:10.3390/molecules27051677 · Cited by 120
“In various experimental kidney disease models, RvD1 was found to restore kidney tubule function, inhibit NF- κB and IL-6 activation [72], increase regulatory T cells, and attenuate tubular injury [73] and to attenuate fibrosis, fibroblast proliferation, and collagen deposition in an experimental model of unilateral ur…”
BackgroundRegulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation
Qu, X., Li, X., Zheng, Y., Ren, Y., Puelles, V. G., Caruana, G., Nikolic-Paterson, D. J., & Li, J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.003 · Cited by 33
Self-citationMechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Metadata
- Authors
- Qu, X., Zhang, X., Yao, J., Song, J., Nikolic‐Paterson, D. J., & Li, J.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2012-11-06
- Volume
- 228
- Issue
- 4
- Pages
- 506-519
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1516619259
- Cited by
- 107
- References
- 6
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.